Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Nordic Nanovector ASA ( (DE:8NN) ) is now available.
Thor Medical ASA has announced the approval of a prospectus for a Subsequent Offering following a successful private placement that raised NOK 157.5 million. The offering aims to raise an additional NOK 27.5 million by issuing up to 11,000,000 new shares to eligible existing shareholders. This strategic financial move, including the listing of new shares on Euronext Oslo Børs, is expected to bolster the company’s capital and potentially enhance its market position. The completion of this offering is contingent upon necessary corporate resolutions, receipt of payment, and registration of the share capital increase.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier in the radiopharmaceutical industry, specializing in radionuclides, primarily alpha particle emitters, derived from naturally occurring thorium. The company employs a proprietary production process that avoids irradiation or nuclear reactors, ensuring a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters. Based in Oslo, Norway, Thor Medical is publicly traded on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
YTD Price Performance: -0.91%
Average Trading Volume: 5,299
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €59.06M
Learn more about 8NN stock on TipRanks’ Stock Analysis page.
